Patterns of care and outcomes among triple‐negative early breast cancer patients in South Western Sydney

Naher, Sayeda; Tognela, Annette; Moylan, Eugene; Adams, Diana; Kiely, Belinda E

doi:10.1111/imj.13628

Cited by 5 publications

(7 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A combinação de mais de uma modalidade de tratamento foi uma conduta comum nos artigos em discussão; a associação de cirurgia e tratamento quimioterápico/radioterápico foi vista como uma maneira eficaz para tratamento do câncer de mama (EVANS et al, 2018;NAHER et al, 2018) Com relação a contraindicação ao tratamento, o estudo 3 (NAHER et al, 2018) mostrou contraindicações ao tratamento quimioterápico: idade, comorbidades, status de desenvolvimento insatisfatório, recusa do paciente. Com relação ao tratamento radioterápico, possuímos contraindicações absolutas, como por exemplo doença multicêntrica, gravidez e margens positivas após várias tentativas de retirada de tumor; e contraindicações relativas, como tratamento prévio de radioterapia no mesmo local e tumor grande em mamas pequenas (NADER MARTA et al, 2011).…”

Section: Resultado E Discussãounclassified

Câncer de mama: diagnóstico e tratamento quimioterápico e radioterápico / Breast cancer: diagnosis, drug terapy and radiotherapy treatment

Severino¹,

Santos²,

Lopes³

et al. 2021

BJDV

View full text Add to dashboard Cite

RESUMOO presente artigo avalia o diagnóstico e o tratamento quimioterápico e radioterápico no câncer de mama. Trata-se de uma revisão integrativa de literatura acerca do diagnóstico e tratamentos quimioterápicos e radioterápicos no câncer de mama. Foi realizado o levantamento artigos no período de janeiro a fevereiro de 2021, nas bases de dados LILACS e MEDLINE, sendo 3 estudos selecionados para discussão. Destes, um tratou acerca da resposta de pacientes ao tratamento ofertado para o câncer, outro sobre o acompanhamento de uma paciente diagnosticada com linfoma primário de mama, e outro acerca das medicações utilizadas em tratamento do câncer. Embora haja diversos tipos de tratamento além dos selecionados pela pesquisa, o tratamento quimioterápico e radioterápico associado a cirurgia de remoção é a principal conduta adotada para tratamento de câncer de mama.

show abstract

Section: Resultado E Discussãounclassified

Câncer de mama: diagnóstico e tratamento quimioterápico e radioterápico / Breast cancer: diagnosis, drug terapy and radiotherapy treatment

Severino¹,

Santos²,

Lopes³

et al. 2021

BJDV

View full text Add to dashboard Cite

show abstract

“…the HR−/ERBB2− subtype. 24,25 Given that patients who were diagnosed with recurrence before the development of CBC were censored at the time of recurrence, the CBC group consisted of patients who did not develop any recurrence in the early phase after PBC, thus substantiating the good prognosis. Despite these results, overall death numbers in each subgroup of the CBC group were too small, thus necessitating studies with larger populations.…”

Section: Discussionmentioning

confidence: 99%

Survival After Development of Contralateral Breast Cancer in Korean Patients With Breast Cancer

Kim,

Yoon,

Kim

et al. 2023

JAMA Netw Open

View full text Add to dashboard Cite

ImportanceContralateral breast cancer (CBC) is the most frequently diagnosed primary cancer in patients with breast cancer. Although many studies have reported survival after the development of CBC, results have been inconsistent.ObjectiveTo investigate whether the development of CBC is associated with survival among patients with breast cancer.Design, Setting, and ParticipantsThis cohort study was conducted at the Asan Medical Center, Korea, among patients who were diagnosed with primary unilateral, nonmetastatic, stage 0 to III breast cancer between 1999 and 2013 and followed up through 2018. The median (IQR) follow-up was 107 (75-143) months. Patients were categorized into CBC and no-CBC groups by whether they developed CBC during the follow-up period. Data were analyzed from November 2021 to March 2023.ExposureDevelopment of CBC.Main outcomes and measuresSurvival rates of CBC and no-CBC groups were compared using a time-dependent Cox proportional hazard model in the entire study population and in subgroup analyses by interval of CBC development and subtype of the primary breast cancer.ResultsAmong 16 251 patients with breast cancer (all Asian, specifically Korean; mean [SD] age, 48.61 [10.06] years), 418 patients developed CBC. There was no significant difference in overall survival between CBC and no-CBC groups (hazard ratio, 1.166; 95% CI, 0.820-1.657). Patients who developed CBC within 1.5 years after the surgery of the primary breast cancer had a higher risk for overall death during the study period (hazard ratio, 2.014; 95% CI, 1.044-3.886), and those who developed CBC after 1.5 years showed no significant difference in survival compared with the no-CBC group. Patients with hormone receptor (HR)–positive and human epidermal growth factor receptor 2 (ERBB2, formerly HER2)–negative breast cancer had a higher risk for overall death in the CBC group (hazard ratio, 1.882; 95% CI, 1.143-3.098) compared with the no-CBC group.Conclusions and RelevanceThis study found that development of CBC in patients with breast cancer was not associated with survival but that early development of CBC after diagnosis of the primary breast cancer or development of CBC in patients with HR-positive/ERBB2-negative breast cancer was associated with survival. These results may provide valuable information for patients seeking advice on opting for contralateral prophylactic mastectomy.

show abstract

“…Higher tumor grades and Ki-67 scores, as well as ductal TNBC, have been shown to have poorer patient outcomes in TNBC. 6–8 , 30 , 35 , 46 , 48 , 50 , 51 …”

Section: Discussionmentioning

confidence: 99%

“…Triple Negative Breast Cancer (TNBC) accounts for approximately 15% of all breast cancer subtypes, 4 , 5 with differing demographic and clinicopathological characteristics to other breast cancers. 6 , 7 TNBC has a poorer prognosis, due to fewer pathways for therapeutics to target. 4 , 5 , 8 TNBCs can be further sub-classified into six different molecular subtypes: two basal-like (BL1 and BL2), mesenchymal, mesenchymal stem-like, immunomodulatory, luminal AR and an unspecified group.…”

Section: Introductionmentioning

confidence: 99%

Androgen Receptor Status in Triple Negative Breast Cancer: Does It Correlate with Clinicopathological Characteristics?

Dubrava,

Kyaw,

Newman

et al. 2023

BCTT

View full text Add to dashboard Cite

Purpose Triple negative breast cancer (TNBC) is a breast carcinoma subtype that neither expresses estrogen (ER) and progesterone receptors (PR) nor the human epidermal growth factor receptor 2 (HER2). Patients with TNBC have been shown to have poorer outcomes mainly owing to the limited treatment options available. However, some studies have shown TNBC tumors expressing androgen receptors (AR), raising hopes of its prognostic role. Patients and Methods This retrospective study investigated the expression of AR in TNBC and its relationship with known patient demographics, tumor and survival characteristics. From the records of 205 TNBC patients, 36 had available archived tissue samples eligible for AR staining. For statistical purposes, tumors were classified as either “positive” or “negative” for AR expression. The nuclear expression of AR was scored by measuring the percentage of stained tumor cells and its staining intensity. Results AR was expressed by 50% of the tissue samples in our TNBC cohort. The relationship between AR status with age at the time of TNBC diagnosis was statistically significant, with all AR positive TNBC patients being greater than 50 years old (vs 72.2% in AR negative TNBC). Also, the relationship between AR status and type of surgery received was statistically significant. There were no statistically significant associations between AR status with other tumor characteristics including “TNM status”, tumor grade or treatments received. There was no statistically significant difference in median survival between AR negative and AR positive TNBC patients (3.5 vs 3.1 years; p = 0.581). The relationship between OS time and AR status (p = 0.581), type of surgery (p = 0.061) and treatments (p = 0.917) were not statistically significant. Conclusion The androgen receptor may be an important prognostic marker in TNBC, with further research warranted. This research may benefit future studies investigating receptor-targeted therapies in TNBC.

show abstract

Patterns of care and outcomes among triple‐negative early breast cancer patients in South Western Sydney

Abstract: TNBC affects women at a relatively young age and tends to recur early. Survival following metastatic disease is short, and more effective therapies are needed.

Cited by 5 publications

References 22 publications

Câncer de mama: diagnóstico e tratamento quimioterápico e radioterápico / Breast cancer: diagnosis, drug terapy and radiotherapy treatment

Câncer de mama: diagnóstico e tratamento quimioterápico e radioterápico / Breast cancer: diagnosis, drug terapy and radiotherapy treatment

Survival After Development of Contralateral Breast Cancer in Korean Patients With Breast Cancer

Androgen Receptor Status in Triple Negative Breast Cancer: Does It Correlate with Clinicopathological Characteristics?

Contact Info

Product

Resources

About